Solid growth and high M&A activity
- Revenue increased by 99 per cent to
EUR 41.5m (20.8), of which 5.5 per cent was organic growth - Adjusted EBITA amounted to
EUR 11.6m (7.7), corresponding to an adjusted EBITA margin of 27.9 percent (37.1) - Operating profit totalled
EUR 4.5m (3.2), including items affecting comparability ofEUR -4.0m (-2.9) - Earnings per share before and after dilution totalled
EUR -0.00 (0.00)
“We report organic growth of 5.5 per cent in the third quarter with maintained positive underlying momentum, although tough comparatives impacts the year over year performance. Excluding Diagnostics, where sales declined as business returned to normal post Covid, organic growth in the quarter was 13.8 per cent. Our Specialty Pharma segment delivers robust underlying growth across all geographies and therapeutic areas. In
Adjusted EBITA increased to
“The lower margin in the quarter mainly reflects developments in the
A telephone and web conference will be held for investors, analysts and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.
To attend the telephone conference:
SE: +46 856642692
US: +164 67224957
To attend the web conference:
Link: https://tv.streamfabriken.com/vimian-group-q3-2021
Related presentation materials will be available at Vimian’s corporate website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.
© Modular Finance, source